He is the Founder and CEO of Mountaineer Biosciences, a consultancy that supports drug discovery and development through strategic guidance on clinical data, regulatory documentation, and therapeutic positioning. He also serves as Co-Founder and Executive at Galileo Biosystems, where he leads R&D for small molecule programs targeting the aryl hydrocarbon receptor across multiple therapeutic areas including oncology, dermatology, and pulmonology. 

Previously, Dr. Howell was Chief Scientific Officer at Zura Bio and DermTech, where he played pivotal roles in clinical strategy and diagnostic innovation. Earlier in his career, he held senior scientific positions at Incyte, MedImmune, and Boehringer Ingelheim, contributing to the development of breakthrough therapies such as ruxolitinib cream, tezepelumab, brodalumab, and SKYRIZI (rizankizumab). 

Dr. Howell began his career in academia and government research, including faculty and research roles at the National Jewish Medical and Research Center and the National Institute for Occupational Safety and Health. He holds multiple scientific advisory and board roles in the biotech sector. 

Dr. Howell holds a Ph.D. in Immunology and continues to shape the future of biotech innovation through strategic advisory, clinical insight, and a deep understanding of immune-mediated diseases.